anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In this trial, a total of 300 adults (at least 18 years of age) diagnosed with irritable bowel syndrome (IBS) in accordance with the Rome IV criteria will be included. Patients will be recruited from gastroenterologists and primary care clinics across the USA. The study product, Fuco-N-Tetraose, will be taken daily throughout the course of the trial. All data will be collected through 4 web based surveys, and the participants will complete those at baseline before the intervention starts, and after 4, 8 and 12 weeks of intake of the study product.

The primary outcome of the study will be assessed by the Patients' Global Impression of Change (PGIC) scale. Other questionnaires used in the study includes the IBS specific Gastrointestinal Symptom Rating Scale (GSRS-IBS), the IBS Quality of Life Scale (IBS-QoL), the Participant Health Questionnaire-4 (PHQ-4), the Participant Health Questionnaire-12 (PHQ-12), and the Bristol Stool Form Scale (BSFS). All outcomes will be evaluated in all patients and in sub-groups of patients. i.e. subtypes by predominant bowel habit (diarrhea-predominant, constipation-predominant, or altered/mixed pattern), and lactose intolerant patients.
Athletic activity may be tracked and monitored while providing encouragement and maintaining an individual's interest in continuing to perform athletic activity. For example, a themed workout plan may be implemented to motivate the individual and maintain the individual's interest. The theme may include geographic locations, food items, technology, sports and the like and may include multiple categories or groupings of goals. For example, the categories may correspond to geographic locations. In each category, multiple goals may be defined. The goals may further be represented by real- world objects such as buildings, food items, technology products, sports equipment and the like. A user may progress through each category by completing each of the goals within that category. Other individuals (e.g., friends) may also be displayed on an interface through which a user's progress is tracked. This may allow the user to also view the other individuals' progress in the same workout plan.
Participants underwent two phases of treatment: an initial DD, followed by a therapeutic dose. The one-day DD comprised a 1 hr IV infusion of 450 mg unlabeled TST, followed by a 20 min IV infusion of 35 mg TST labeled with 185 MBq (5.0 mCi) of I 131. After 7 to 14 days, the one-day therapeutic dose comprised a second 1 hr IV infusion of 450 mg unlabeled TST, followed by a 20 min IV infusion of 35 mg TST labeled with I 131 with an administered activity (MBq or mCi) determined from the dosimetry calculation.
Patients with wounds that meet eligibility criteria will be randomized, if randomized to the Standard Gauze Dressing Arm, a saline moistened sterile gauze will be packed into the wound with dry gauze and either tape or other means will be used to secure the dressing. The dressing will be changed daily and measured and photodocumented every 72 hours with the Wound Zoom system.
PURPOSE: To obtain an ultraviolet-intercepting agent which is excellent in ultraviolet-intercepting effect, is a fine powder excellent in dispersion stability, and is so chemically stable that it, hardly undergoes changes in quality, by using a layered silicate mineral which contains metal ions intercalated between layers. CONSTITUTION: Metal ions are selected from among the groups of iron, aluminum, titanium, zinc, copper alkaline earth metals, and chromium. A layered silicate mineral as the raw material is a clay mineral belonging to the smectite group, including montmorillonite, etc. The intercalation is done by using a salt of one of the above metals (e.g. iron chloride), i.e., subjecting the silicate mineral to water elutriation, removing the precipitate, adding the salt to the supernatant liq., and conducting the intercalation under stirring at room temp., a pH of 10 or lower, and a cation-exchange rate of 90% or higher. The resulting product is filtered to separate solids, and the solids are dried and ground to give the objective product. The salt is added in an amt. of 3-20wt.% of the silicate mineral.
It is a prospective and pilot study of RCT. It will be a pilot to test the acceptability and feasibility of a two-armed tele-exercise RCT to mitigate symptoms and improve health for breast cancer survivors. In this study, outcome assessors and data analysts will be masked from the allocation results. The pilot will recruit 24 patients and randomly assign them to an intervention group (Group A) and an active control group (Group B). All participants in both groups will continue receiving usual care from the study hospital during the study period. Additionally, those in Group A (intervention) will receive the tele-exercise (12 home-based online training sessions + 4 psychological counselling sessions), while those in Group B (active control) will receive 4 essays on exercise and health. Outcome measurements will be repeatedly performed before and after the intervention.
The skin will be disinfected with 2% chlorhexidine. Under sterile technique, the epidural will be placed. Epidural catheter will be placed at thoracic vertebral levels T5 to T10. Level chosen as clinically indicated. The epidural solution should contain institution's standard solution of Bupivicaine 0.05% and hydromorphone 10 mcg/cc. However, solution type should be clinically indicated.
PURPOSE: A zwitterion-coated MRI(magnetic resonance imaging) contrast agent is provided to maintain uniform size and high super-paramagnetic property, and to improve water dispersion and stability of a ferric oxide nanoparticle. CONSTITUTION: An MRI contrast agent contains: a core part(10) containing a ferric oxide nanoparticle; and a hydrophilic coating layer(22) which is coated on the surface of the core part and contains an amphoteric ion(20). The ferric oxide nanoparticle is Fe_3O_4. The diameter of the core part is 1-500 nm. The thickness of the hydrophilic coating layer is 1-100 nm. The surface of the core part is coated with a hydrophilic coating layer(12) containing C15-25 fatty acid or a derivative thereof.
Enhanced invasion and migration of non-small cell lung cancer (NSCLC) cells is the major cause of metastasis and poor prognosis in NSCLC. This study was conducted to investigate the role and mechanism of lncRNA KCNQ1OT1 in the proliferation, invasion, and migration of NSCLC cells. The expression of KCNQ1OT1 in NSCLC was analyzed in the StarBase database, and the target miRNA of KCNQ1OT1 as well as the target genes of the miRNA was predicted. Then, the mRNA expression levels of KCNQ1OT1, miR-496, and HMGB1 were detected in clinical tissue samples and cells by qRT-PCR assay. Besides, the protein levels of HMGB1 were detected by Western blot. MTT assay, transwell assay, and scratch assay were used to determine the proliferation, invasion, and migration ability of NSCLC cells, respectively. Correlation analysis was performed to assess the correlation between the expression of KCNQ1OT1, miR-496, and HMGB1 in clinical NSCLC samples. Dual-luciferase reporter gene assay was conducted to analyze the interaction between KCNQ1OT1 and miR-496 and between miR-496 and HMGB1. The database results showed that KCNQ1OT1 was highly expressed in NSCLC. Similarly, we found that the expression level of KCNQ1OT1 was significantly higher in NSCLC tissues and cells than that in the corresponding normal tissues and cells. The results of MTT assay, transwell assay, and scratch assay demonstrated that KCNQ1OT1 significantly enhanced the proliferation, invasion, and migration of NSCLC cells. Further mechanism exploration revealed that KCNQ1OT1 could sponge miR-496, and miR-496 directly targeted and regulated the expression of HMGB1. The expression of miR-496 and either KCNQ1OT1 or HMGB1 were negatively correlated in NSCLC, while the expression of KCNQ1OT1 and HMGB1 were positively correlated. Compared with normal paracancer tissues, miR-496 was much lower and HMGB1 was much higher expressed in NSCLC tissues. The results of cotransfection also further demonstrated that miR-496 inhibitor or sh-HMGB1 cotransfected with sh-KCNQ1OT1 could significantly decrease or increase the ability of sh-KCNQ1OT1 to inhibit the proliferation, invasion, and migration of H1299 cells, respectively. In conclusion, lncRNA KCNQ1OT1 promotes the invasion and migration of NSCLC cells through miR-496/HMGB1 signaling axis.
BACKGROUND: The aim of this systematic review and meta-analysis was to analyse the efficacy of azithromycin in acute bronchiolitis and wheezing.
METHODS: PubMed, Scopus, and Web of Science databases were searched for randomized controlled trials comparing azithromycin to placebo in children <2 years of age. Main outcomes were progress of acute wheezing episode and recurrence of wheezing. We used random-effects model to calculate mean difference (MD) with 95% confidence interval (CI) or risk ratios (RR) with CI.
RESULTS: We screened 1604 abstracts and included 7 studies. Risk of bias was low in three and had some concerns in four studies. Need for intensive care unit treatment was assessed in four studies (446 children) and the risk difference was 0.0% (CI -2.0 to 2.0; low quality evidence). Hospitalization duration was -0.27 days shorter in the azithromycin group (MD-0.27, CI -0.47 to -0.07; three studies; moderate quality evidence). Azithromycin did not prevent recurrence of wheezing (RR 0.84, CI 0.45-1.56; three studies), hospital readmissions (RR 1.14, CI 0.82-1.60; four studies).
CONCLUSIONS: We found moderate quality evidence that azithromycin may reduce hospitalization duration. Low certainty evidence suggests that azithromycin does not reduce the need for intensive care unit treatment. Furthermore, azithromycin did not prevent wheezing recurrence.
IMPACT: Azithromycin may reduce hospitalization time in acute bronchiolitis and wheezing episodes among children aged less than two. Azithromycin administrated during the acute wheezing period, does not have preventive effect on wheezing recurrence. Azithromycin seemed to have similar adverse event profile than placebo. Future studies with clinically relevant outcomes, and sufficient sample sizes are needed, before implementing azithromycin into clinical use.
This includes toxicity arising from accidental intravascular injection of Ultacan® or Ultacan® forte discussed in Section 5.1, as well as that related to higher systemic concentrations of local anesthetics or epinephrine [see Warnings and Precautions (5.3)]. Systemic absorption of local anesthetics including Ultacan® or Ultacan® forte can produce effects on the central nervous and cardiovascular systems.

At blood concentrations achieved with therapeutic doses of Ultacan® or Ultacan® forte , changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance are minimal. However, toxic blood concentrations of Ultacan® or Ultacan® forte can depress cardiac conduction and excitability, which may lead to atrioventricular block, ventricular arrhythmias, and cardiac arrest, possibly resulting in fatalities. In addition, myocardial contractility is depressed and peripheral vasodilatation occurs, leading to decreased cardiac output and arterial blood pressure. Ultacan® or Ultacan® forte should also be used with caution in patients with heart block as well as those with impaired cardiovascular function since they may be less able to compensate for functional changes associated with the prolongation of A-V conduction produced by these drugs.

Restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of central nervous system toxicity.

Careful and constant monitoring of cardiovascular and respiratory (adequacy of ventilation) vital signs and the patient’s state of consciousness should be performed after each local anesthetic injection of Ultacan® or Ultacan® forte . Repeated doses of Ultacan® or Ultacan® forte may cause significant increases in blood levels because of possible accumulation of the drug or its metabolites. The lowest dosage that results in effective anesthesia should be used to decrease the risk of high plasma levels and serious adverse effects. Tolerance to elevated blood levels varies with the status of the patient. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use. Precautions for epinephrine administration, discussed in Section 5.3, should be observed.

Debilitated patients, elderly patients, acutely ill patients, and pediatric patients should be given reduced doses commensurate with their age and physical condition [see Dosage and Administration (2.1, 2.3)]. No studies have been performed in patients with liver dysfunction, and caution should be used in patients with severe hepatic disease.
<P>PROBLEM TO BE SOLVED: To provide a lotion composition for imparting soft and smooth touch feeling to tissue paper.  <P>SOLUTION: The lotion composition is such as to be intended for imparting the touch feeling to tissue paper when about 5 to about 15 wt.% thereof is added to the tissue paper. Tissue paper treated with such a lotion composition is also provided. The lotion composition comprises a plastic or fluid emollient such as petrolatum, or a mixture of petrolatum with an alkyl ethoxylate emollient, an immobilizing agent such as a fatty alcohol or fatty acid to immobilize the emollient on the surface of tissue paper web 1 and optionally a hydrophilic surfactant to improve wettability when added to tissue paper. Because only a small amount of the lotion composition is enough to impart desired soft and lotion-like touch feeling to tissue paper, detrimental effects on the tensile strength and thickness of the resulting lotioned paper are minimized or avoided.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Cosmetic composition comprising, in a cosmetically acceptable medium, an aqueous dispersion of insoluble particles of a film-forming polymer and a non-amino alpha , omega -disilanol silicone emulsion.- DETAILED DESCRIPTION - The aqueous dispersion is preferably obtained by (co)polymerisation of monomers selected from styrene, butadiene, ethylene, propylene, vinyl toluene, vinyl propionate, vinyl alcohol, acrylonitrile, chloroprene, vinyl acetate, urethanes, isoprene, isobutene, vinyl ether, vinylpyrrolidone, vinylimidazole, (meth)acrylic acid, maleic acid, crotonic acid, or itaconic acid or esters or amides of these acids. The concentration of polymer particles is preferably 1-35 wt. % on total composition. The silicone is selected e.g. from polydialkylsiloxane alpha , omega - disilanols, polyalkylaryl alpha , omega -disilanols, and polydiaryldialkyl alpha , omega -disilanols. The non-amino alpha , omega -disilanol silicones are present in an amount of 0.05-10 (0.1-3) wt. % on total composition. The compositions may be in the form of lotions for application to the hair as styling or conditioning lotions, or they can be packaged under pressure with at least one propellant for application as an aerosol spray. The propellant is present e.g. in an amount of 5- 90 (10-50) % on the total weight of the pressurized composition
This study aimed to develop and validate a multi-modality radiomics approach using T1-weighted and diffusion tensor imaging (DTI) to differentiate Parkinson's disease (PD) motor subtypes, specifically tremor-dominant (TD) and postural instability gait difficulty (PIGD), in early disease stages. We analyzed T1-weighted and DTI scans from 140 early-stage PD patients (70 TD, 70 PIGD) and 70 healthy controls from the Parkinson's Progression Markers Initiative database. Radiomics features were extracted from 16 brain regions of interest. After harmonization and feature selection, four machine learning classifiers were trained and evaluated for both three-class (HC vs TD vs PIGD) and binary (TD vs PIGD) classification tasks. The light gradient boosting machine (LGBM) classifier demonstrated the best overall performance. For the three-class classification, LGBM achieved an accuracy of 85% and an area under the receiver operating characteristic curve (AUC) of 0.94 using combined T1 and DTI features. In the binary classification task, LGBM reached an accuracy of 95% and AUC of 0.95. Key discriminative features were identified in the Thalamus, Amygdala, Hippocampus, and Substantia Nigra for the three-group classification, and in the Pallidum, Amygdala, Hippocampus, and Accumbens for binary classification. The combined T1 + DTI approach consistently outperformed single-modality classifications, with DTI alone showing particularly low performance (AUC 0.55-0.62) in binary classification. The high accuracy and AUC values suggest that this approach could significantly improve early diagnosis and subtyping of PD. These findings have important implications for clinical management, potentially enabling more personalized treatment strategies based on early, accurate subtype identification.
The application provides ibuprofen particles and a preparation method thereof, wherein the method comprises the following steps: crushing the raw material medicines: the ibuprofen raw material medicine is crushed to specified fineness to obtain a first raw material medicine. Raw and auxiliary material sieving: and sieving the adhesive, the first raw material medicine and the filler to obtain the raw and auxiliary materials with preset meshes. Preparing a mixed solution: the flavoring agent and correctant are dissolved in purified water according to the prescription. Mixing: adding the raw and auxiliary materials with preset meshes and the disintegrating agent into a mixing machine, mixing the raw and auxiliary materials and the disintegrating agent into dry powder, and adding the mixed solution for wet mixing to obtain a soft material. A granulation step: and extruding the soft material through a granulator to obtain wet granules. And (3) drying: the wet granulation is dried to obtain dry granulation. Finishing the grains: and removing large particles and fine powder in the dry particles to obtain the target ibuprofen particles. The application improves the combination degree of the raw material medicines, the raw and auxiliary materials and the adhesive, and further improves the uniformity and the dissolution performance of the medicine.
The leukocyte immunoglobulin-like receptor (LILR) family, a group of primate-specific immunoreceptors, is widely expressed on most immune cells and regulates immune responses through interactions with various ligands. The inhibitory type, LILRB, has been extensively studied, and many ligands, such as HLA class I, have been identified. However, the activating type, LILRA, is less understood. We have previously identified microbially cleaved immunoglobulin as a non-self-ligand for LILRA2. In this study, we identified fibrinogen as an endogenous ligand for LILRA2 using mass spectrometry. Although human plasma contains fibrinogen in abundance in its soluble form, LILRA2 only recognizes solid-phase fibrinogen. In addition to the activating LILRA2, fibrinogen was also recognized by the inhibitory LILRB2 and by soluble LILRA3. In contrast, fibrin was recognized by LILRB2 and LILRA3, but not by LILRA2. Moreover, LILRA3 bound more strongly to fibrin than to fibrinogen and blocked the LILRB2-fibrinogen/fibrin interaction. These results suggest that morphological changes in fibrinogen determine whether activating or inhibitory immune responses are induced. Upon recognizing solid-phase fibrinogen, LILRA2 activated human primary monocytes and promoted the expression of various inflammation-related genes, such as chemokines, as revealed by RNA-seq analysis. A blocking antibody against LILRA2 inhibited the fibrinogen-induced inflammatory responses, indicating that LILRA2 is the primary receptor of fibrinogen. Taken together, our findings suggest that solid-phase fibrinogen is an inflammation-inducing endogenous ligand for LILRA2, and this interaction may represent a novel therapeutic target for inflammatory diseases.
BACKGROUND: Children with under-five year age disproportionally affected with foodborne illness. Campylobacteriosis is the most common foodborne disease next to Norovirus infection. Macrolides are commonly prescribed as the first line of treatment for Campylobacter gastroenteritis, with fluoroquinolone and tetracycline as secondary options. However, resistance to these alternatives has been reported in various regions worldwide.
OBJECTIVE: To determine the prevalence, associated risk-factors and antimicrobial resistance of Campylobacter jejuni and C. coli among under-five children with diarrhea.
METHODS: Institution-based cross-sectional study was conducted from November, 2022 to April 2023. The study sites were selected using a random sampling technique, while the study subjects were included using a convenient sampling technique. The data were collected using a structured questionnaire. Stool samples were inoculated onto modified charcoal cefoperazone deoxycholate agar and incubated for 48 hours. The suspected colonies were analyzed using matrix-assisted laser desorption ionization-time of flight mass spectrometry to confirm the species. Antimicrobial susceptibility testing was performed using a disc diffusion technique. All potential covariates (independent variables) were analyzed one by one using bivariate logistic regression model to identify candidate variables with P value < 0.25. Multivariable logistic analysis was used to identify potential associated factors using the candidate variables. A p value ≤ 0.05 at a 95% confidence interval was statistically significant.
RESULT: Among the 428 samples, 7.0% (CI: 4.5-9.3) were confirmed Campylobacter species. The prevalence of C. jejuni and C. coli among under-five children was 5.1% (CI: 3.0-7.0) and 1.9% (CI: 0.7-3.3), respectively. C. jejuni (73.3%) was dominant over C. coli (26.7%). The resident, contact with domestic animals, and parents/guardians education level were significantly associated with campylobacteriosis among under-five children. One-third of the Campylobacter isolates (33.3%, 10/30) were resistant to ciprofloxacin and tetracycline whereas 10.0% (3/30) were resistant to erythromycin. Furthermore, 3.3% (1/30) of the Campylobacter were found to be multidrug-resistant.
CONCLUSION: The prevalence of Campylobacter species was 7.0%. The resistance rate of Campylobacter species of ciprofloxacin and tetracycline-resistance strains was 33.3%. Peri-urban residence, contact with domestic animals, and low parental educational statuses were significantly associated factors with increased risk of Campylobacter infection. Continuous surveillance on antimicrobial resistance and health education of personal and environmental hygiene should be implemented in the community.
A glucose solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.